Abbott Laboratories Reports Solid Q1 2024 Results with Strong Growth and Strategic Advancements
Wednesday, 17 April 2024, 17:30
Abbott Laboratories Q1 2024 Earnings Call Highlights
Abbott Laboratories reported first-quarter adjusted earnings per share of $0.98, exceeding analyst estimates. The company raised its full-year guidance ranges, showcasing continued momentum and growth across its diversified portfolio.
Financial Results and Outlook
- Organic sales growth of 4.7% in Q1 2024
- Full-year adjusted EPS forecast raised to $4.55-$4.70
- Organic sales growth range adjusted to 8.5%-10%
Strategic Advancements and Product Performance
- Significant growth in medical devices, diagnostics, and established pharmaceuticals
- Continuous product approvals and clinical milestones achievement
- Expansion opportunities in medical device segments, including structural heart and diabetics care
Abbott Laboratories demonstrates strong growth, strategic advancements, and a competitive advantage in the healthcare market, positioning the company for continued success and innovation.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.